These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 19036146)

  • 1. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
    Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
    Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
    BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
    Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
    Sansonno D; Lauletta G; Russi S; Conteduca V; Sansonno L; Dammacco F
    Oncologist; 2012; 17(3):359-66. PubMed ID: 22334456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
    TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
    Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
    Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
    Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Pawlik TM; Reyes DK; Cosgrove D; Kamel IR; Bhagat N; Geschwind JF
    J Clin Oncol; 2011 Oct; 29(30):3960-7. PubMed ID: 21911714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    Zhang L; Hu P; Chen X; Bie P
    PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
    Cabrera R; Pannu DS; Caridi J; Firpi RJ; Soldevila-Pico C; Morelli G; Clark V; Suman A; George TJ; Nelson DR
    Aliment Pharmacol Ther; 2011 Jul; 34(2):205-13. PubMed ID: 21605146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
    Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
    Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
    Hepatol Int; 2016 May; 10(3):501-10. PubMed ID: 26856326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
    Li Y; Huang JW; Lu LG; Shao PJ; Hu BS; Huang GM; Wei ZG; Zhang L
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2187-92. PubMed ID: 21029658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.